Aziyo Biologics, Inc. (NASDAQ:AZYO – Get Rating) saw a large decline in short interest in the month of November. As of November 30th, there was short interest totalling 3,200 shares, a decline of 55.6% from the November 15th total of 7,200 shares. Based on an average daily volume of 21,000 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.1% of the shares of the company are sold short.
Aziyo Biologics Price Performance
NASDAQ:AZYO opened at $3.64 on Thursday. The firm has a market cap of $50.14 million, a PE ratio of -1.28 and a beta of -0.54. Aziyo Biologics has a 12 month low of $3.51 and a 12 month high of $9.01. The company has a quick ratio of 0.83, a current ratio of 1.09 and a debt-to-equity ratio of 1.34. The company's 50-day moving average price is $6.83 and its two-hundred day moving average price is $6.71.
Get
Aziyo Biologics alerts:
Aziyo Biologics (NASDAQ:AZYO – Get Rating) last released its quarterly earnings results on Monday, November 14th. The company reported ($0.73) EPS for the quarter, missing analysts' consensus estimates of ($0.66) by ($0.07). The firm had revenue of $12.39 million during the quarter, compared to analyst estimates of $12.20 million. Aziyo Biologics had a negative net margin of 77.08% and a negative return on equity of 1,819.23%. On average, equities analysts anticipate that Aziyo Biologics will post -2.63 EPS for the current fiscal year.
Insider Transactions at Aziyo Biologics
In related news, Director Highcape Capital, L.P. acquired 735,000 shares of the company's stock in a transaction dated Monday, December 5th. The shares were bought at an average price of $4.75 per share, for a total transaction of $3,491,250.00. Following the acquisition, the director now owns 5,597,604 shares in the company, valued at approximately $26,588,619. The transaction was disclosed in a legal filing with the SEC, which is available through
this hyperlink. In related news, Director Highcape Capital, L.P. acquired 735,000 shares of the company's stock in a transaction dated Monday, December 5th. The shares were bought at an average price of $4.75 per share, for a total transaction of $3,491,250.00. Following the acquisition, the director now owns 5,597,604 shares in the company, valued at approximately $26,588,619. The transaction was disclosed in a legal filing with the SEC, which is available through
this hyperlink. Also, CFO Matthew Ferguson bought 22,000 shares of the firm's stock in a transaction dated Monday, December 5th. The shares were acquired at an average price of $4.65 per share, for a total transaction of $102,300.00. Following the completion of the transaction, the chief financial officer now owns 45,217 shares in the company, valued at approximately $210,259.05. The disclosure for this purchase can be found
here. In the last 90 days, insiders have purchased 765,000 shares of company stock worth $3,625,030. 39.90% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Aziyo Biologics
A hedge fund recently raised its stake in Aziyo Biologics stock. Endurant Capital Management LP lifted its stake in shares of Aziyo Biologics, Inc. (NASDAQ:AZYO – Get Rating) by 3.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,109,479 shares of the company's stock after purchasing an additional 33,839 shares during the period. Aziyo Biologics makes up about 1.7% of Endurant Capital Management LP's investment portfolio, making the stock its 16th biggest position. Endurant Capital Management LP owned approximately 8.18% of Aziyo Biologics worth $6,601,000 as of its most recent filing with the Securities and Exchange Commission. 24.52% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
AZYO has been the topic of several recent research reports. Truist Financial lifted their target price on shares of Aziyo Biologics from $8.00 to $10.00 and gave the company a "buy" rating in a research report on Wednesday, November 16th. Piper Sandler lifted their target price on shares of Aziyo Biologics from $9.00 to $10.50 and gave the company an "overweight" rating in a research report on Tuesday, November 15th.
Aziyo Biologics Company Profile
(Get Rating)
Aziyo Biologics, Inc, a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device.
Recommended Stories
- Get a free copy of the StockNews.com research report on Aziyo Biologics (AZYO)
- Inflation and the Energy Crisis are Two Freight Trains on a Collision Course – Here's How to Prepare
- Is Enterprise Products Partners Fairly Valued?
- Will WhatsApp Partnership Boost MercadoLibre's Earnings?
- 3 Mid-Caps That Could Double in 2023
- Mullen Automotive Shares Jump After Signing New Partner
Receive News & Ratings for Aziyo Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aziyo Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
